Brighton Jones LLC boosted its holdings in shares of bluebird bio Inc (NASDAQ:BLUE) by 4.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 35,181 shares of the biotechnology company’s stock after buying an additional 1,369 shares during the period. bluebird bio makes up approximately 0.8% of Brighton Jones LLC’s investment portfolio, making the stock its 20th largest position. Brighton Jones LLC’s holdings in bluebird bio were worth $6,266,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the business. NuWave Investment Management LLC acquired a new position in bluebird bio in the 4th quarter worth about $135,000. Swiss National Bank increased its position in bluebird bio by 10.1% in the 4th quarter. Swiss National Bank now owns 82,607 shares of the biotechnology company’s stock worth $14,712,000 after purchasing an additional 7,600 shares during the last quarter. Lisanti Capital Growth LLC increased its position in bluebird bio by 40.7% in the 4th quarter. Lisanti Capital Growth LLC now owns 3,110 shares of the biotechnology company’s stock worth $554,000 after purchasing an additional 900 shares during the last quarter. California Public Employees Retirement System increased its position in bluebird bio by 11.6% in the 4th quarter. California Public Employees Retirement System now owns 96,046 shares of the biotechnology company’s stock worth $17,106,000 after purchasing an additional 9,946 shares during the last quarter. Finally, Teacher Retirement System of Texas increased its position in bluebird bio by 317.2% in the 4th quarter. Teacher Retirement System of Texas now owns 15,383 shares of the biotechnology company’s stock worth $2,740,000 after purchasing an additional 11,696 shares during the last quarter.

In related news, COO Susanna Gatti High sold 1,282 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $172.15, for a total transaction of $220,696.30. Following the completion of the sale, the chief operating officer now owns 13,718 shares in the company, valued at approximately $2,361,553.70. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Nick Leschly sold 5,435 shares of the stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $173.38, for a total value of $942,320.30. Following the sale, the chief executive officer now owns 171,009 shares of the company’s stock, valued at approximately $29,649,540.42. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 200,280 shares of company stock valued at $37,818,846. 3.90% of the stock is owned by corporate insiders.

BLUE has been the topic of several research reports. Wedbush reaffirmed an “outperform” rating and issued a $174.00 target price (up from $135.00) on shares of bluebird bio in a research report on Thursday, November 2nd. Evercore ISI upgraded bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 price target for the company in a research note on Monday, October 16th. BMO Capital Markets upped their price target on bluebird bio from $134.00 to $162.00 and gave the stock a “buy” rating in a research note on Monday, October 30th. Maxim Group set a $170.00 price target on bluebird bio and gave the stock a “buy” rating in a research note on Friday, November 17th. Finally, BidaskClub downgraded bluebird bio from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 16th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $161.45.

Shares of bluebird bio Inc (NASDAQ:BLUE) opened at $197.50 on Tuesday. bluebird bio Inc has a 52 week low of $73.95 and a 52 week high of $222.03. The firm has a market capitalization of $9,050.00, a P/E ratio of -28.17 and a beta of 2.07.

TRADEMARK VIOLATION NOTICE: This article was first reported by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.watchlistnews.com/bluebird-bio-inc-blue-position-lifted-by-brighton-jones-llc/1862627.html.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.